Objectives. To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically meaningful changes in score

A. Prabu

A. Rahman

Abrahamowicz

B. Griffiths

Bombardier

Brunner

C. Edwards

C. Gordon

C.-S. Yee

Chang

D. A. Isenberg

D. D'Cruz

Fortin

Furie

Gladman

Guzm  n

Hawker

Hochberg

Husted

I. N. Bruce

L.-S. Teh

Liang

M. A. Khamashta

M. Akil

N. McHugh

Petri

Schisterman

V. T. Farewell

Ward

Wollaston

Y. Ahmad

Zweig

English

PubMed

Objectives. To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically meaningful changes in score. Methods. Data from two multi-centre studies were used in the analysis: in a cross-sectional and a longitudinal fashion. At every assessment, data were collected on SLEDAI-2000 and treatment. The cross-sectional analysis with receiver operating characteristic (ROC) curves was used to examine the appropriate SLEDAI-2000 score to define active disease and increase in therapy was the reference standard. In the longitudinal analysis, sensitivity to change of SLEDAI-2000 was assessed with multinomial logistic regression. ROC curves analysis was used to examine possible cut-points in score changes associated with change in therapy, and mean changes were estimated. Results. In the cross-sectional analysis, the most appropriate cut-off scores for active disease were 3 or 4. In the longitudinal analysis, the best model for predicting treatment increase was with the change in SLEDAI-2000 score and the score from the previous visit as continuous variables. The use of cut-points was less predictive of treatment change than the use of continuous score. The mean difference in the change in SLEDAI-2000 scores, adjusted for prior score, between patients with treatment increase and those without was 2.64 (95% CI 2.16, 3.14). Conclusions. An appropriate SLEDAI-2000 score to define active disease is 3 or 4. SLEDAI-2000 index is sensitive to change. The use of SLEDAI-2000 as a continuous outcome is recommended for comparative purposes

Yee, Chee

Farewell, VT

Isenberg, DA

Griffiths, B

Teh, LS

Bruce, IN

Ahmad, Yasmin

Rahman, A

Prabu, Athiveeraramapandian

Akil, M

McHugh, N

Edwards, C

D'Cruz, D

Khamashta, MA

Gordon, Caroline

University of Birmingham Research Portal

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

Objectives: To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically meaningful changes in score. Methods: Data from two multi-centre studies were used in the analysis: in a cross-sectional and a longitudinal fashion. At every assessment, data were collected on SLEDAI-2000 and treatment. The cross-sectional analysis with receiver operating characteristic (ROC) curves was used to examine the appropriate SLEDAI-2000 score to define active disease and increase in therapy was the reference standard. In the longitudinal analysis, sensitivity to change of SLEDAI-2000 was assessed with multinomial logistic regression. ROC curves analysis was used to examine possible cut-points in score changes associated with change in therapy, and mean changes were estimated. Results: In the cross-sectional analysis, the most appropriate cut-off scores for active disease were 3 or 4. In the longitudinal analysis, the best model for predicting treatment increase was with the change in SLEDAI-2000 score and the score from the previous visit as continuous variables. The use of cut-points was less predictive of treatment change than the use of continuous score. The mean difference in the change in SLEDAI-2000 scores, adjusted for prior score, between patients with treatment increase and those without was 2.64 (95% CI 2.16, 3.14). Conclusions: An appropriate SLEDAI-2000 score to define active disease is 3 or 4. SLEDAI-2000 index is sensitive to change. The use of SLEDAI-2000 as a continuous outcome is recommended for comparative purposes. © The Author(s) 2011. Published by Oxford University Press on behalf of The British Society for Rheumatology

Yee, Chee Seng

Farewell, Vernon T.

Isenberg, David A.

Griffiths, Bridget

Teh, Lee Suan

Bruce, Ian N.

Ahmad, Yasmeen

Rahman, Anisur

Akil, Mohammed

McHugh, Neil

Edwards, Christopher

D'Cruz, David

Khamashta, Munther A.

The University of Manchester - Institutional Repository

The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

Crossref

Rheumatology

Objectives: To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically meaningful changes in score.Methods: Data from two multi-centre studies were used in the analysis: in a cross-sectional and a longitudinal fashion. At every assessment, data were collected on SLEDAI-2000 and treatment. The cross-sectional analysis with receiver operating characteristic (ROC) curves was used to examine the appropriate SLEDAI-2000 score to define active disease and increase in therapy was the reference standard. In the longitudinal analysis, sensitivity to change of SLEDAI-2000 was assessed with multinomial logistic regression. ROC curves analysis was used to examine possible cut-points in score changes associated with change in therapy, and mean changes were estimated.Results: In the cross-sectional analysis, the most appropriate cut-off scores for active disease were 3 or 4. In the longitudinal analysis, the best model for predicting treatment increase was with the change in SLEDAI-2000 score and the score from the previous visit as continuous variables. The use of cut-points was less predictive of treatment change than the use of continuous score. The mean difference in the change in SLEDAI-2000 scores, adjusted for prior score, between patients with treatment increase and those without was 2.64 (95% CI 2.16, 3.14).Conclusions: An appropriate SLEDAI-2000 score to define active disease is 3 or 4. SLEDAI-2000 index is sensitive to change. The use of SLEDAI-2000 as a continuous outcome is recommended for comparative purposes

Yee, Chee-Seng

Teh, Lee-Suan

Southampton (e-Prints Soton)

A note on robust variance estimation for cluster-correlated data.

A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus.

Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

British Isles Lupus Assessment Group

Combined oral contraceptives in women with systemic lupus erythematosus.

Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.

Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.

Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus.

Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.

Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum

Derivation of the SLEDAI. A disease activity index for lupus patients.

Do lupus disease activity measures detect clinically important change?

Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices.

Methods for assessing responsiveness: a critical review and recommendations.

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum

Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology

Prabu A et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem

Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). App Stat 1994;43:

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum

revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum

Sensitivity of the systemic lupus erythematosus disease activity index, british isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum

Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation.

Systemic lupus erythematosus disease activity index

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology

The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials.

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:

Validity and reliability of lupus activity measures in the routine clinic setting.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3077910

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

Abstract

Similar works

Full text

Available Versions

University of Birmingham Research Portal

The University of Manchester - Institutional Repository

University of Birmingham Research Portal

Crossref

Southampton (e-Prints Soton)